ライフサイエンスコーパス: ebolavirus

1 e expressing a surface glycoprotein of Zaire Ebolavirus.

2 the surface structure and entry functions of ebolavirus.

3 ebolavirus, Zaire ebolavirus, and Bundibugyo ebolavirus.

4 fective against viruses of the species Zaire ebolavirus.

5 igenically distinct species within the genus Ebolavirus.

6 cephus) from Cameroon was positive for Sudan ebolavirus.

7 ucleotide substitutions/site/year for Reston ebolavirus.

8 es treated after lethal challenge with Zaire ebolavirus.

9 of two antibodies that cooperatively target Ebolaviruses.

10 t occur in Sudan, Bundibugyo, and Tai Forest ebolaviruses.

11 tations may result in novel human pathogenic Ebolaviruses.

12 d protective efficacy against three virulent ebolaviruses.

13 izing antibodies against multiple species of ebolaviruses.

14 eston viruses from the four human pathogenic Ebolaviruses.

15 n the development of countermeasures against ebolaviruses.

16 viruses in the Filoviradae family, including ebolaviruses.

17 functions, and protection against the three ebolaviruses.

18 irus (SUDV), as well as other wild-type (WT) ebolaviruses.

19 due to its high sequence conservation among ebolaviruses.

20 t affinities and specificities for different Ebolaviruses.

21 30% identical between Marburg virus and the ebolaviruses.

22 in (GP), do not protect against heterologous ebolaviruses.

23 to induce broad protection against the three ebolaviruses.

24 hat bats are also natural reservoirs for the ebolaviruses.

25 en human pathogenic and non-human pathogenic Ebolaviruses.

26 utic countermeasure to antigenically diverse ebolaviruses.

27 inst homologous and not against heterologous ebolaviruses.

28 reporter cell line capable of detecting live ebolaviruses.

29 ed recombinant VSV encoding GP1,2 from these ebolaviruses.

30 ity of amino acids with the human pathogenic Ebolaviruses (63.25%).

31 Ebolavirus, a deadly hemorrhagic fever virus, was though

32 a phenotype similar to that of GP from Zaire ebolavirus, a highly pathogenic species, in terms of bot

33 GP from Reston ebolavirus, a nonpathogenic species in humans, showed a

34 Since VP24 is critical for Ebolavirus adaptation to novel hosts, and only a few SDP

35 are protected from disease on infection with ebolaviruses, although adapted versions of some of the v

36 There are five species of ebolavirus; among these, the Ebola (Zaire) and Sudan vir

37 frica, other ebolavirus species (e.g., Sudan ebolavirus and Bundibugyo ebolavirus) have also repeated

38 ibugyo virus (BDBV) is a member of the genus Ebolavirus and has caused outbreaks in the past but is r

39 Ebolavirus and Marburgvirus cause severe hemorrhagic fev

40 SV)-based filovirus vaccine vectors using wt Ebolavirus and Marburgvirus challenge strains.

41 Viruses in the Ebolavirus and Marburgvirus genera (family Filoviridae)

42 conserved epitope within the fusion loop of ebolavirus and marburgvirus species.

43 virus and differentiated between the genera Ebolavirus and Marburgvirus The amount of filovirus RNA

44 The investigational Ebolavirus and Marburgvirus WT GP DNA vaccines were safe

45 for replication of nonadapted wild-type (wt) Ebolavirus and Marburgvirus.

46 Here we report the development of pan-ebolavirus and pan-filovirus antibodies generated by rep

47 Here we report a set of pan-ebolavirus and pan-filovirus monoclonal antibodies (MAbs

48 re also important for rational design of pan-ebolavirus and pan-filovirus vaccines.

49 While there are five species of Ebolavirus and several strains of marburgvirus, the curr

50 ack only within the last 50 years for Reston ebolavirus and Zaire ebolavirus species and suggests tha

51 MBP134 potently neutralized all ebolaviruses and demonstrated greater protective efficac

52 Ebolaviruses and marburgviruses belong to the family Fil

53 nt and balanced responses against individual ebolaviruses and no significant reduction of the respons

54 induced neutralizing responses to all three ebolaviruses and protected animals from death and diseas

55 lenges of diseases caused by infections with ebolaviruses and questioned scientific, clinical, and so

56 For almost 50 years, ebolaviruses and related filoviruses have been repeatedl

57 ng positions; SDPs) between human pathogenic Ebolaviruses and the non-pathogenic Reston virus.

58 ecies of Ebolavirus (Zaire ebolavirus, Sudan ebolavirus, and Bundibugyo ebolavirus) associated with h

59 , Reston ebolavirus, Sudan ebolavirus, Zaire ebolavirus, and Bundibugyo ebolavirus.

60 s are hosts of a range of viruses, including ebolaviruses, and many important human viral infections,

61 ectrum activity of broadly neutralizing anti-ebolavirus antibodies (Abs) outside of the internal fusi

62 ating in close contact with humans, and anti-Ebolavirus antibodies that may indicate contact with Bom

63 Multiple pan-ebolavirus antibodies were identified that react to the

64 irus (EBOV)-specific and, more recently, pan-ebolavirus antibody cocktails have been described.

65 provides a promising option for broad-acting ebolavirus antibody therapy and will accelerate the desi

66 In the Gulu case, ebolavirus antigen localized to malarial parasite pigmen

67 Ebolavirus antigen was seen in the syncytiotrophoblast a

68 Ebolaviruses are pathogenic agents associated with a sev

69 y Bray and by Lever et al suggesting that WT ebolaviruses are pathogenic in mice deficient for the ty

70 mutation may be unique to the species Zaire ebolavirus, as it does not occur in Sudan, Bundibugyo, a

71 virus (EBOV), and ineffective against other ebolaviruses associated with EVD, including Sudan virus

72 as limited their use against other divergent ebolaviruses associated with human disease.

73 ebolavirus, Sudan ebolavirus, and Bundibugyo ebolavirus) associated with human disease, with no cross

74 Zaire ebolavirus (EBOV), Bundibugyo ebolavirus (BDBV), and Reston ebolavirus (RESTV) belong

75 Marburg virus (MARV) and the ebolaviruses belong to the family Filoviridae (the membe

76 ses and found two antibodies that showed pan-ebolavirus binding.

77 We examined the disease course of several WT ebolaviruses: Boneface (SUDV/Bon) and Gulu variants of S

78 facilitated the discovery of not only a new ebolavirus, but also three new filovirus genera and a si

79 , but not parent mAbs, neutralized all known ebolaviruses by coopting viral particles themselves for

80 Most ebolaviruses can cause severe disease in humans and othe

81 Ebolaviruses cause a severe hemorrhagic fever syndrome t

82 Ebolaviruses cause severe hemorrhagic fever.

83 The recent West African outbreak of ebolavirus caused the deaths of more than 11,000 individ

84 Ebola virus (EBOV), formerly Zaire ebolavirus, causes a severe hemorrhagic disease in human

85 Reston virus (RESTV), an ebolavirus, causes clinical disease in macaques but has

86 of nonhuman primates from lethal homologous Ebolavirus challenge.

87 irus miRNA target genes, we suggest that two ebolavirus coding possible miRNAs may be silence and dow

88 Ebolaviruses constitute a public health threat, particul

89 Modern ebolavirus diagnostics rely primarily on quantitative re

90 o documented infection but immunoreactive to ebolavirus did not neutralize.

91 eral thousand people have been killed by the Ebolavirus disease (EVD) in West Africa, yet no current

92 Ebolavirus disease causes high mortality, and the curren

93 Ebolavirus disease is a global threat.

94 pathology and immune-mediated cell damage in ebolavirus disease often result in severe compromise of

95 CE The symptoms of the disease caused by the ebolaviruses Ebola, Bundibugyo, and Sudan are similar, a

96 diagnostic test for rapid detection of Zaire ebolavirus (EBOV) and Sudan ebolavirus (SUDV).

97 Virologic investigation identified Zaire ebolavirus (EBOV) as the causative agent.

98 Zaire ebolavirus (EBOV) causes Ebola virus disease (EVD), whic

99 otective immunity against acute lethal Zaire ebolavirus (EBOV) challenge in macaques, but fail to pro

100 on of host factors that are needed for Zaire Ebolavirus (EBOV) entry provides insights into the mecha

101 es (MAbs; c2G4, c4G7, and c13C6) against the ebolavirus (EBOV) glycoprotein (GP), shows promise for c

102 antibodies and cellular immune responses to Ebolavirus (EBOV) glycoprotein.

103 atality rate (90%) similar to that for Zaire ebolavirus (EBOV) infection.

104 Transport of ebolavirus (EBOV) nucleocapsids from perinuclear viral i

105 Zaire ebolavirus (EBOV) VP35 is a double-stranded RNA (dsRNA)-

106 Viable Zaire ebolavirus (EBOV) was detected in aqueous humor 14 weeks

107 Ebolavirus (EBOV), an enveloped filamentous RNA virus ca

108 Zaire ebolavirus (EBOV), Bundibugyo ebolavirus (BDBV), and Res

109 he family Filoviridae contains three genera, Ebolavirus (EBOV), Marburg virus, and Cuevavirus.

110 5 inhibits multiple viruses, including Zaire ebolavirus (EBOV), Rift Valley fever virus (RVFV), Venez

111 roving its protective efficacy against three Ebolaviruses: EBOV, SUDV, and BDBV.

112 evidence that in contrast to the new model, ebolavirus enters cells through endolysosomes that conta

113 ternate model was recently proposed in which ebolavirus enters through a later NPC1-negative endosome

114 Ca(2+) channel 2 (TPC2), a newly identified ebolavirus entry factor.

115 binding to GP, neutralization of individual ebolaviruses, epitope specificity, Fc-mediated functions

116 Additionally, the ebolavirus exploits the miRNAs to inhibit the NF-kB and

117 and Bombali viruses, the marburgviruses and ebolaviruses (family Filoviridae) cause outbreaks of vir

118 If correct, this would distinguish the ebolaviruses from other NNS RNA viruses.

119 et of SDPs that distinguish human pathogenic Ebolaviruses from Reston virus.

120 We determined structures of the Ebolavirus fusion loop and found residues critical for f

121 Here, we include the many Ebolavirus genome sequences that have since become avail

122 Here, using the genome-wide screening in ebolavirus genome sequences, we predicted four putative

123 The use of 1408 Ebolavirus genomes (196 in the original analysis) result

124 We analyzed 196 Ebolavirus genomes and identified specificity determinin

125 cording to published sequences, both ends of ebolavirus genomes show a high degree of variability, an

126 Using Ebolavirus genomic and epidemiological data, we conducte

127 Hypothesizing that the closely related Ebolavirus genus may share the same Achilles' heel, we r

128 Three Ebolavirus genus viruses cause lethal disease and lack t

129 and Reston virus (RESTV) are members of the Ebolavirus genus which greatly differ in their pathogeni

130 24 proteins from EBOV and two members of the Ebolavirus genus, Bundibugyo virus (BDBV) and Reston vir

131 ment are specific for a single member of the Ebolavirus genus, Ebola virus (EBOV), and ineffective ag

132 tics are specific for a single member of the Ebolavirus genus, Ebola virus (EBOV), and ineffective ag

133 rus sdAb, that was cross-reactive within the Ebolavirus genus, recognized a similar structural featur

134 agent driven antigen sandwich assays for the Ebolavirus genus.

135 , indicating epitope conservation across the Ebolavirus genus.

136 an adenovirus type 5 vectors (rAd5) encoding ebolavirus glycoprotein (GP) generate protective immunit

137 of the limited antigenic relatedness of the ebolavirus glycoprotein (GP) used in all candidate vacci

138 alizing mAbs that cooperatively bound to the ebolavirus glycoprotein (GP).

139 Several monoclonal antibodies against the ebolavirus glycoprotein are currently in development as

140 ch of the MAbs in this cocktail binds to the ebolavirus glycoprotein as it is displayed-embedded in t

141 prime-boost vaccination regimen with a Zaire ebolavirus glycoprotein expression plasmid followed by i

142 and more complete picture of the accessible Ebolavirus glycoprotein landscape and a structural basis

143 ibes the generation of a panel of novel anti-ebolavirus glycoprotein monoclonal antibodies, including

144 cocktail of three MAbs directed against the ebolavirus glycoprotein, is a promising anti-ebolavirus

145 Here we report the generation of an ebolavirus glycoprotein-specific monoclonal antibody tha

146 icular stomatitis virus expressing the Zaire ebolavirus glycoprotein.

147 lnerability in an internal fusion loop of an ebolavirus glycoprotein.

148 icular stomatitis virus expressing the Zaire ebolavirus glycoprotein.

149 ernal fusion loop with the N terminus of the ebolavirus glycoproteins (GPs) and potently neutralizes

150 ted transmembrane-deleted and point-mutation Ebolavirus glycoproteins (GPs) in candidate vaccines.

151 omatitis virus (rVSV) pseudotypes expressing Ebolavirus glycoproteins (GPs) in place of the VSV G pro

152 s that exist in culture conditions and among ebolavirus glycoproteins.

153 d epitopes in this area neutralized all five ebolaviruses, guiding the development of a pan-ebolaviru

154 ainst the individual viral proteins of Sudan ebolavirus (Gulu) in human survivors was performed.

155 the search for the natural reservoirs of the ebolaviruses has largely involved serosurveillance of th

156 Ebolaviruses have a surface glycoprotein (GP1,2) that is

157 Four species of ebolaviruses have been identified in west or equatorial

158 31,100 cases since their discovery in 1976, ebolaviruses have caused approximately 13,000 deaths.

159 Together, our data show that ebolaviruses have evolved a unique replication strategy

160 ecies (e.g., Sudan ebolavirus and Bundibugyo ebolavirus) have also repeatedly caused outbreaks in Cen

161 inguish Reston virus VP24 from VP24 of other Ebolaviruses, human pathogenic Reston viruses may emerge

162 2H7), might add to the understanding of anti-ebolavirus humoral immunity.IMPORTANCE This study descri

163 The ebolavirus immunotherapeutics field has replaced previou

164 Pan-Ebolavirus immunotherapy would provide a rapid-response

165 olaviruses, guiding the development of a pan-ebolavirus immunotherapy.

166 ization was notified of an outbreak of Zaire ebolavirus in a remote area of Guinea.

167 bition of the class I fusion glycoprotein of Ebolavirus In the current work, several promising small-

168 for Bundibugyo, Sudan, and Zaire species of Ebolavirus in the domestic ferret, using wild-type nonad

169 sons who had occupational exposures to Zaire ebolavirus in West Africa received investigational agent

170 vided full protection against all pathogenic ebolaviruses in mice, guinea pigs, and ferrets.

171 red postexposure protection against multiple ebolaviruses in mice.

172 NP) appear to be major virulence factors for ebolaviruses in rodents, whereas VP40 appears to be the

173 e) species is the most lethal species of all ebolaviruses in terms of mortality rate and number of de

174 cap-specific mAbs that neutralized multiple ebolaviruses, including SUDV, and a cross-reactive mAb t

175 revealed a potential mechanism of miRNAs in ebolavirus infection and possible therapeutic targets fo

176 th monoclonal antibodies isolated from human ebolavirus infection survivors demonstrated that the imm

177 better understand humoral immunity following ebolavirus infection, a serological study of the humoral

178 okine storm" that is characteristic of fatal ebolavirus infection.

179 approved for the prevention or treatment of ebolavirus infection.

180 zing antibodies are highly effective against ebolavirus infections, current experimental ebolavirus v

181 y-based treatment effective against multiple Ebolavirus infections.

182 w its protective efficacy in mouse models of ebolavirus infections.

183 t are useful for clinical diagnosis of acute ebolavirus infections.

184 re a promising treatment option for managing ebolavirus infections.

185 NPC1) have been reported to promote entry of ebolaviruses into certain cellular systems.

186 Ebolavirus is a highly lethal pathogen, causing a severe

187 Ebolavirus is an enveloped virus causing severe hemorrha

188 Zaire ebolavirus is the causative agent of the current outbrea

189 Furthermore, VP24 from the ebolaviruses is immunosuppressive, while that of Marburg

190 broadly neutralizing antibodies (bNAbs) for ebolaviruses is possible but difficult, potentially due

191 The Zaire Ebolavirus kit is based on the Filovirus Screen kit but

192 ch with a distinct function required for the ebolavirus life cycle.

193 ulties accessing the populations affected by ebolaviruses, little is also known about what constitute

194 that a cocktail of two broadly neutralizing ebolavirus mAbs, FVM04 and CA45, protects nonhuman prima

195 These results provide a functional model for ebolavirus matrix assembly and the other roles of VP40 i

196 hat antibody-mediated protection against the Ebolaviruses may be achievable, but little is known abou

197 Host cell factors required for spread of ebolaviruses may serve as targets for antiviral interven

198 Ebola virus (EBOV), species Zaire ebolavirus, may persist in the semen of male survivors o

199 ics analysis and prediction of the potential ebolavirus miRNA target genes, we suggest that two ebola

200 dentified mAbs with exceptionally potent pan-ebolavirus neutralizing activity and protective efficacy

201 so reveal lucrative opportunities within the ebolavirus NP C-termini that might be leveraged for diag

202 a similar structural feature upstream of the ebolavirus NP C-terminus.

203 The C-terminal domain of Ebolavirus NP is a strong attractant for antibodies and

204 ntrations of 20-nt target sequences from the Ebolavirus nucleoprotein gene in a constant-temperature

205 Growing understanding of ebolavirus pathogenetic mechanisms and important new cli

206 viously identified potential determinants of Ebolavirus pathogenicity in humans by analysing the amin

207 Ebolaviruses pose significant public health problems due

208 The ongoing evolution of Ebolaviruses poses significant challenges to the develop

209 reveal the antibody response against all ebolavirus proteins by analyzing longitudinal antibody r

210 ity determining positions (SDPs) in all nine Ebolavirus proteins that distinguish Reston viruses from

211 novel functional insights in particular for Ebolavirus proteins VP40 and VP24.

212 (EVD) underscore the unpredictable nature of ebolavirus reemergence and the urgent need for antiviral

213 aimed at establishing natural reservoir host-ebolavirus relationships.

214 cacy, rodent models have been widely used in ebolavirus research because of their convenience.

215 A major obstacle in ebolavirus research is the lack of a small-animal model

216 Ebola virus (EBOV) (genera Marburgvirus and Ebolavirus, respectively).

217 us species: Marburg marburgvirus, Tai Forest ebolavirus, Reston ebolavirus, Sudan ebolavirus, Zaire e

218 V), Bundibugyo ebolavirus (BDBV), and Reston ebolavirus (RESTV) belong to the same genus but exhibit

219 th Sudan virus (SUDV), a member of the genus Ebolavirus, result in a severe hemorrhagic fever with a

220 Whereas the 5' ends of ebolavirus RNAs are highly conserved with the sequence A

221 (RT-PCR) kit and the derived RealStar Zaire Ebolavirus RT-PCR kit were validated using in vitro tran

222 e expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a promising Ebola vaccine can

223 ficities of a less cross-reactive anti-Zaire ebolavirus sdAb and a totally specific anti-Sudan ebolav

224 virus sdAb and a totally specific anti-Sudan ebolavirus sdAb were the result of exclusion from this r

225 treated in parallel with heterologous Sudan ebolavirus (SEBOV) convalescent macaque sera, and 2 anim

226 (MARV), Zaire ebolavirus (ZEBOV), and Sudan ebolavirus (SEBOV), cause severe and often fatal hemorrh

227 ound in any Sudan, Bundibugyo, or Tai Forest ebolavirus sequences.

228 l tool for identifying bat species with high ebolavirus seroprevalence rates to target for longitudin

229 in Central and, recently, West Africa, other ebolavirus species (e.g., Sudan ebolavirus and Bundibugy

230 he differences in pathogenicity reported for ebolavirus species and suggest that proinflammatory path

231 ast 50 years for Reston ebolavirus and Zaire ebolavirus species and suggests that viruses within thes

232 imental and clinical samples, independent of ebolavirus species and variant.

233 bodies binding to the core GP1 region of all ebolavirus species and with lower affinity to MARV GP cr

234 Different ebolavirus species are associated with widely varying pa

235 s determining the pathogenicity of different ebolavirus species are not yet known.

236 iruses within Marburg marburgvirus and Sudan ebolavirus species can be traced back further and share

237 Reston virus, the only non-human pathogenic Ebolavirus species circulates in pigs in Asia, this rais

238 ntry of representative isolates of all known ebolavirus species in vitro and show its protective effi

239 ve antibodies that bind the GPs of all known Ebolavirus species will give us important insight into t

240 -targeting antibodies cross-react with other Ebolavirus species, and detailed epitope mapping reveale

241 react between the glycoproteins of different ebolavirus species, and the mechanism of these monoclona

242 d antigenomic nucleotides of three different ebolavirus species, Ebola (EBOV), Sudan, and Reston viru

243 heir breadth of reactivity against different ebolavirus species, predict viral evasion against these

244 tection against viruses belonging to diverse Ebolavirus species, such as Ebola virus (EBOV), Sudan vi

245 to the antigenic differences among the five ebolavirus species, the current therapeutic monoclonal a

246 the basis of sequence homology between the 5 Ebolavirus species, we hypothesize that conserved epitop

247 y and protection is observed between these 5 Ebolavirus species, which complicates vaccine developmen

248 ies with broad cross-reactivity to all known ebolavirus species.

249 hogenicity between Reston and the other four ebolavirus species.

250 lized both SUDV and EBOV, the most divergent ebolavirus species.

251 LISA as cross-reacting with the GPs of all 5 Ebolavirus species.

252 ed serological assays to screen bat sera for ebolavirus-specific IgG antibodies.

253 assay platforms for detecting VP40 and other ebolavirus-specific immunoglobulins.

254 The Sudan ebolavirus-specific sdAb was more remarkable and appeare

255 Specificity, in the case of the Zaire ebolavirus-specific sdAb, arose from the footprint shift

256 study investigates the viability of 2 Zaire ebolavirus strains within aerosols at 22 degrees C and 8

257 utbreak caused by other members of the genus Ebolavirus, such as Sudan virus (SUDV), is not readily a

258 ensitivity to 3 species of Ebolavirus (Zaire ebolavirus, Sudan ebolavirus, and Bundibugyo ebolavirus)

259 marburgvirus, Tai Forest ebolavirus, Reston ebolavirus, Sudan ebolavirus, Zaire ebolavirus, and Bund

260 Besides EBOV, two additional ebolaviruses, Sudan (SUDV) and Bundibugyo (BDBV) viruses

261 udinal serum samples from survivors of Sudan ebolavirus (SUDV) infection, studied over years, were ex

262 ct against other Ebola species such as Sudan ebolavirus (SUDV).

263 tection of Zaire ebolavirus (EBOV) and Sudan ebolavirus (SUDV).

264 t respiratory syndrome coronavirus and Zaire Ebolavirus templates into glucose signals, with a sensit

265 Reston viruses are the only Ebolaviruses that are not pathogenic in humans.

266 Here we show that MBP134(AF), a pan-ebolavirus therapeutic comprising two broadly neutralizi

267 Ab cocktail suitable for evaluation as a pan-ebolavirus therapeutic in nonhuman primates.

268 ebolavirus glycoprotein, is a promising anti-ebolavirus therapeutic.

269 SUDV GP binding affinity, as a candidate pan-ebolavirus therapeutic.

270 indings should inform future developments of ebolavirus therapeutics.

271 ade in developing therapeutics against Zaire ebolavirus, these therapies do not protect against other

272 nucleotide substitutions/site/year for Sudan ebolavirus to 8.21 x 10(-4) nucleotide substitutions/sit

273 However, the factors used by ebolaviruses to invade macrophages, major viral targets,

274 The potential of the Bombali virus, a novel Ebolavirus, to cause disease in humans remains unknown.

275 fection may be a mechanism of transplacental ebolavirus transmission.

276 binant chimpanzee adenovirus type 3-vectored ebolavirus vaccine (cAd3-EBO), encoding the glycoprotein

277 ve important implications for developing pan-ebolavirus vaccine and immunotherapeutic cocktails.

278 Therefore, a broadly specific pan-ebolavirus vaccine is required, and this might be achiev

279 comolar affinity, suggesting that engineered ebolavirus vaccines could trigger rare bNAb precursors m

280 Thus, administration of a cocktail of three ebolavirus vaccines induces a desirable broad antibody r

281 The effects of cocktail administration of ebolavirus vaccines on the antibody repertoire remain un

282 ebolavirus infections, current experimental ebolavirus vaccines primarily elicit species-specific an

283 t a high titer of Ebola virus (species Zaire ebolavirus) variant Makona in spiked human serum samples

284 Crystal structures of ebolavirus VP35 show that it caps dsRNA ends to prevent

285 V) containing the envelope proteins of Zaire ebolavirus (VSV-ZEBOV) or severe acute respiratory syndr

286 type 3-vectored vaccines against individual ebolaviruses was performed, which included analysis of b

287 Systematic investigation of ebolavirus whole genomes during the 2014 outbreak may sh

288 in this trial encode wild-type (WT) GP from Ebolavirus Zaire and Sudan species and the Marburgvirus

289 Ebolaviruses Zaire (EBOV), Bundibugyo (BDBV), and Sudan

290 RDT demonstrated sensitivity to 3 species of Ebolavirus (Zaire ebolavirus, Sudan ebolavirus, and Bund

291 Forest ebolavirus, Reston ebolavirus, Sudan ebolavirus, Zaire ebolavirus, and Bundibugyo ebolavirus.

292 use diagnostic assays for detection of Zaire ebolavirus (ZEBOV) are urgently needed.

293 ine-mediated protection against lethal Zaire ebolavirus (ZEBOV) challenge.

294 Zaire Ebolavirus (ZEBOV) continues to pose a significant threa

295 irus (rVSV)-based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid s

296 to treat patients during outbreaks of Zaire ebolavirus (ZEBOV) infection in 1976 and 1995, with inco

297 The most recent Zaire Ebolavirus (ZEBOV) outbreak was the largest and most wid

298 e encoding the surface glycoprotein of Zaire ebolavirus (ZEBOV) to 60 healthy adult volunteers in Oxf

299 oviruses, Marburg marburgvirus (MARV), Zaire ebolavirus (ZEBOV), and Sudan ebolavirus (SEBOV), cause

300 e members of the EBOV genus, including Zaire ebolavirus (ZEBOV), can cause lethal haemorrhagic fever